Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints
The fosfomycin breakpoint using the disc diffusion method (DDM) changed in the 2019 CA-SFM/EUCAST guidelines v2 (24mm versus 19mm). We assessed its impact on categorization of Enterobacterales recovered from urine samples in emergency departments. A total of 7749 and 2348 strains were tested using t...
Gespeichert in:
| Veröffentlicht in: | Médecine et maladies infectieuses 2020-10, Vol.50 (7), p.611-616 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 616 |
|---|---|
| container_issue | 7 |
| container_start_page | 611 |
| container_title | Médecine et maladies infectieuses |
| container_volume | 50 |
| creator | Farfour, E. Degand, N. Riverain, E. Fihman, V. Le Brun, C. Péan de Ponfilly, G. Muggeo, A. Jousset, A. Piau, C. Lesprit, P. Chatelain, N. Dortet, L. Poisson, A. Guillard, T. Limelette, A. Mizrahi, A. Le Monnier, A. Fournier, D. Potron, A. Morand, P. Janvier, F. Otto, M.-P. Woerther, P.-L. Decousser, J.-W. Corvec, S. Plouzeau-Jayle, C. Broutin, L. Yin, N. Héry-Arnaud, G. Beauruelle, C. Grillon, A. Lecuru, M. Bille, E. Godreuil, S. Jean Pierre, H. Amara, M. Henry, A. Zahar, J.-R. Carbonelle, E. Jaureguy, F. Lomont, A. Isnard, C. Cattoir, V. Canis, F. Diedrich, T. Flevin, E. Merens, A. Jacquier, H. Gyde, E. |
| description | The fosfomycin breakpoint using the disc diffusion method (DDM) changed in the 2019 CA-SFM/EUCAST guidelines v2 (24mm versus 19mm). We assessed its impact on categorization of Enterobacterales recovered from urine samples in emergency departments. A total of 7749 and 2348 strains were tested using the DDM and the broth microdilution method (BMD), respectively. The DDM with the 19-mm breakpoint was in accordance with the BMD. Using the 24-mm breakpoint, the overall rate of fosfomycin resistance in Enterobacterales increased by three-fold (5.6% vs 18.1%, P |
| doi_str_mv | 10.1016/j.medmal.2020.07.003 |
| format | Article |
| fullrecord | <record><control><sourceid>hal</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04226097v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_04226097v1</sourcerecordid><originalsourceid>FETCH-hal_primary_oai_HAL_hal_04226097v13</originalsourceid><addsrcrecordid>eNqVys1KAzEUQOEsFFurb-DibgWb3iRlwrgTsVRw6ULcDOn0jk3Nz5CbKvP2IvgCrg58HCFuFEqFqlkdZaR9dEFq1CjRSkRzJuZo2naJ1r7NxCXzEVFrVHghZkY3tjVrPRfvm8xDjlPv0x0MJUfgE_c0Vr_zwdcJaoZC7Lm61NM9PMfR9RXyAPVAkOgbPk5-T8EnYsgJdoXc55h9qnwlzgcXmK7_uhC3m6fXx-3y4EI3Fh9dmbrsfLd9eOl-DddaN9jaL2X-8_4AoMBPQA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints</title><source>Elsevier ScienceDirect Journals</source><creator>Farfour, E. ; Degand, N. ; Riverain, E. ; Fihman, V. ; Le Brun, C. ; Péan de Ponfilly, G. ; Muggeo, A. ; Jousset, A. ; Piau, C. ; Lesprit, P. ; Chatelain, N. ; Dortet, L. ; Poisson, A. ; Guillard, T. ; Limelette, A. ; Mizrahi, A. ; Le Monnier, A. ; Fournier, D. ; Potron, A. ; Morand, P. ; Janvier, F. ; Otto, M.-P. ; Woerther, P.-L. ; Decousser, J.-W. ; Corvec, S. ; Plouzeau-Jayle, C. ; Broutin, L. ; Yin, N. ; Héry-Arnaud, G. ; Beauruelle, C. ; Grillon, A. ; Lecuru, M. ; Bille, E. ; Godreuil, S. ; Jean Pierre, H. ; Amara, M. ; Henry, A. ; Zahar, J.-R. ; Carbonelle, E. ; Jaureguy, F. ; Lomont, A. ; Isnard, C. ; Cattoir, V. ; Canis, F. ; Diedrich, T. ; Flevin, E. ; Merens, A. ; Jacquier, H. ; Gyde, E.</creator><creatorcontrib>Farfour, E. ; Degand, N. ; Riverain, E. ; Fihman, V. ; Le Brun, C. ; Péan de Ponfilly, G. ; Muggeo, A. ; Jousset, A. ; Piau, C. ; Lesprit, P. ; Chatelain, N. ; Dortet, L. ; Poisson, A. ; Guillard, T. ; Limelette, A. ; Mizrahi, A. ; Le Monnier, A. ; Fournier, D. ; Potron, A. ; Morand, P. ; Janvier, F. ; Otto, M.-P. ; Woerther, P.-L. ; Decousser, J.-W. ; Corvec, S. ; Plouzeau-Jayle, C. ; Broutin, L. ; Yin, N. ; Héry-Arnaud, G. ; Beauruelle, C. ; Grillon, A. ; Lecuru, M. ; Bille, E. ; Godreuil, S. ; Jean Pierre, H. ; Amara, M. ; Henry, A. ; Zahar, J.-R. ; Carbonelle, E. ; Jaureguy, F. ; Lomont, A. ; Isnard, C. ; Cattoir, V. ; Canis, F. ; Diedrich, T. ; Flevin, E. ; Merens, A. ; Jacquier, H. ; Gyde, E.</creatorcontrib><description>The fosfomycin breakpoint using the disc diffusion method (DDM) changed in the 2019 CA-SFM/EUCAST guidelines v2 (24mm versus 19mm). We assessed its impact on categorization of Enterobacterales recovered from urine samples in emergency departments. A total of 7749 and 2348 strains were tested using the DDM and the broth microdilution method (BMD), respectively. The DDM with the 19-mm breakpoint was in accordance with the BMD. Using the 24-mm breakpoint, the overall rate of fosfomycin resistance in Enterobacterales increased by three-fold (5.6% vs 18.1%, P<0.01) and reached 2.8% and 86.5% in E. coli and K. pneumoniae, respectively. French guidelines for the management of community-acquired UTI remain appropriate. The accuracy of the methods for routine fosfomycin susceptibility testing should be assessed. The role of fosfomycin in the treatment of documented CA-UTI due to Enterobacterales other than E. coli should be evaluated considering its rate of resistance and recent data reporting low accuracy.</description><identifier>ISSN: 0399-077X</identifier><identifier>DOI: 10.1016/j.medmal.2020.07.003</identifier><identifier>PMID: 32679342</identifier><language>eng</language><publisher>Elsevier Masson</publisher><subject>Anti-Bacterial Agents ; Bacteria ; Drug Resistance, Bacterial ; Environmental Sciences ; Fosfomycin ; Microbial Sensitivity Tests ; Practice Guidelines as Topic</subject><ispartof>Médecine et maladies infectieuses, 2020-10, Vol.50 (7), p.611-616</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-4041-9696 ; 0000-0002-4228-3868 ; 0000-0002-7131-9882 ; 0000-0001-6596-7384 ; 0000-0002-2966-7947 ; 0000-0001-6181-281X ; 0000-0002-6163-2947 ; 0000-0003-3243-8018 ; 0000-0001-7432-1657 ; 0000-0003-3511-2005 ; 0000-0002-6957-9482 ; 0000-0001-9172-0510 ; 0000-0002-9846-0210 ; 0000-0002-2089-3825 ; 0000-0001-7105-6202 ; 0000-0002-6163-2947 ; 0000-0001-6596-7384 ; 0000-0001-7105-6202 ; 0000-0001-6181-281X ; 0000-0002-6957-9482 ; 0000-0002-4228-3868 ; 0000-0002-9846-0210 ; 0000-0003-3243-8018 ; 0000-0003-3511-2005 ; 0000-0002-2966-7947 ; 0000-0001-7432-1657 ; 0000-0002-7131-9882 ; 0000-0002-4041-9696 ; 0000-0001-9172-0510</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://univ-fcomte.hal.science/hal-04226097$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Farfour, E.</creatorcontrib><creatorcontrib>Degand, N.</creatorcontrib><creatorcontrib>Riverain, E.</creatorcontrib><creatorcontrib>Fihman, V.</creatorcontrib><creatorcontrib>Le Brun, C.</creatorcontrib><creatorcontrib>Péan de Ponfilly, G.</creatorcontrib><creatorcontrib>Muggeo, A.</creatorcontrib><creatorcontrib>Jousset, A.</creatorcontrib><creatorcontrib>Piau, C.</creatorcontrib><creatorcontrib>Lesprit, P.</creatorcontrib><creatorcontrib>Chatelain, N.</creatorcontrib><creatorcontrib>Dortet, L.</creatorcontrib><creatorcontrib>Poisson, A.</creatorcontrib><creatorcontrib>Guillard, T.</creatorcontrib><creatorcontrib>Limelette, A.</creatorcontrib><creatorcontrib>Mizrahi, A.</creatorcontrib><creatorcontrib>Le Monnier, A.</creatorcontrib><creatorcontrib>Fournier, D.</creatorcontrib><creatorcontrib>Potron, A.</creatorcontrib><creatorcontrib>Morand, P.</creatorcontrib><creatorcontrib>Janvier, F.</creatorcontrib><creatorcontrib>Otto, M.-P.</creatorcontrib><creatorcontrib>Woerther, P.-L.</creatorcontrib><creatorcontrib>Decousser, J.-W.</creatorcontrib><creatorcontrib>Corvec, S.</creatorcontrib><creatorcontrib>Plouzeau-Jayle, C.</creatorcontrib><creatorcontrib>Broutin, L.</creatorcontrib><creatorcontrib>Yin, N.</creatorcontrib><creatorcontrib>Héry-Arnaud, G.</creatorcontrib><creatorcontrib>Beauruelle, C.</creatorcontrib><creatorcontrib>Grillon, A.</creatorcontrib><creatorcontrib>Lecuru, M.</creatorcontrib><creatorcontrib>Bille, E.</creatorcontrib><creatorcontrib>Godreuil, S.</creatorcontrib><creatorcontrib>Jean Pierre, H.</creatorcontrib><creatorcontrib>Amara, M.</creatorcontrib><creatorcontrib>Henry, A.</creatorcontrib><creatorcontrib>Zahar, J.-R.</creatorcontrib><creatorcontrib>Carbonelle, E.</creatorcontrib><creatorcontrib>Jaureguy, F.</creatorcontrib><creatorcontrib>Lomont, A.</creatorcontrib><creatorcontrib>Isnard, C.</creatorcontrib><creatorcontrib>Cattoir, V.</creatorcontrib><creatorcontrib>Canis, F.</creatorcontrib><creatorcontrib>Diedrich, T.</creatorcontrib><creatorcontrib>Flevin, E.</creatorcontrib><creatorcontrib>Merens, A.</creatorcontrib><creatorcontrib>Jacquier, H.</creatorcontrib><creatorcontrib>Gyde, E.</creatorcontrib><title>Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints</title><title>Médecine et maladies infectieuses</title><description>The fosfomycin breakpoint using the disc diffusion method (DDM) changed in the 2019 CA-SFM/EUCAST guidelines v2 (24mm versus 19mm). We assessed its impact on categorization of Enterobacterales recovered from urine samples in emergency departments. A total of 7749 and 2348 strains were tested using the DDM and the broth microdilution method (BMD), respectively. The DDM with the 19-mm breakpoint was in accordance with the BMD. Using the 24-mm breakpoint, the overall rate of fosfomycin resistance in Enterobacterales increased by three-fold (5.6% vs 18.1%, P<0.01) and reached 2.8% and 86.5% in E. coli and K. pneumoniae, respectively. French guidelines for the management of community-acquired UTI remain appropriate. The accuracy of the methods for routine fosfomycin susceptibility testing should be assessed. The role of fosfomycin in the treatment of documented CA-UTI due to Enterobacterales other than E. coli should be evaluated considering its rate of resistance and recent data reporting low accuracy.</description><subject>Anti-Bacterial Agents</subject><subject>Bacteria</subject><subject>Drug Resistance, Bacterial</subject><subject>Environmental Sciences</subject><subject>Fosfomycin</subject><subject>Microbial Sensitivity Tests</subject><subject>Practice Guidelines as Topic</subject><issn>0399-077X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqVys1KAzEUQOEsFFurb-DibgWb3iRlwrgTsVRw6ULcDOn0jk3Nz5CbKvP2IvgCrg58HCFuFEqFqlkdZaR9dEFq1CjRSkRzJuZo2naJ1r7NxCXzEVFrVHghZkY3tjVrPRfvm8xDjlPv0x0MJUfgE_c0Vr_zwdcJaoZC7Lm61NM9PMfR9RXyAPVAkOgbPk5-T8EnYsgJdoXc55h9qnwlzgcXmK7_uhC3m6fXx-3y4EI3Fh9dmbrsfLd9eOl-DddaN9jaL2X-8_4AoMBPQA</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Farfour, E.</creator><creator>Degand, N.</creator><creator>Riverain, E.</creator><creator>Fihman, V.</creator><creator>Le Brun, C.</creator><creator>Péan de Ponfilly, G.</creator><creator>Muggeo, A.</creator><creator>Jousset, A.</creator><creator>Piau, C.</creator><creator>Lesprit, P.</creator><creator>Chatelain, N.</creator><creator>Dortet, L.</creator><creator>Poisson, A.</creator><creator>Guillard, T.</creator><creator>Limelette, A.</creator><creator>Mizrahi, A.</creator><creator>Le Monnier, A.</creator><creator>Fournier, D.</creator><creator>Potron, A.</creator><creator>Morand, P.</creator><creator>Janvier, F.</creator><creator>Otto, M.-P.</creator><creator>Woerther, P.-L.</creator><creator>Decousser, J.-W.</creator><creator>Corvec, S.</creator><creator>Plouzeau-Jayle, C.</creator><creator>Broutin, L.</creator><creator>Yin, N.</creator><creator>Héry-Arnaud, G.</creator><creator>Beauruelle, C.</creator><creator>Grillon, A.</creator><creator>Lecuru, M.</creator><creator>Bille, E.</creator><creator>Godreuil, S.</creator><creator>Jean Pierre, H.</creator><creator>Amara, M.</creator><creator>Henry, A.</creator><creator>Zahar, J.-R.</creator><creator>Carbonelle, E.</creator><creator>Jaureguy, F.</creator><creator>Lomont, A.</creator><creator>Isnard, C.</creator><creator>Cattoir, V.</creator><creator>Canis, F.</creator><creator>Diedrich, T.</creator><creator>Flevin, E.</creator><creator>Merens, A.</creator><creator>Jacquier, H.</creator><creator>Gyde, E.</creator><general>Elsevier Masson</general><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-4041-9696</orcidid><orcidid>https://orcid.org/0000-0002-4228-3868</orcidid><orcidid>https://orcid.org/0000-0002-7131-9882</orcidid><orcidid>https://orcid.org/0000-0001-6596-7384</orcidid><orcidid>https://orcid.org/0000-0002-2966-7947</orcidid><orcidid>https://orcid.org/0000-0001-6181-281X</orcidid><orcidid>https://orcid.org/0000-0002-6163-2947</orcidid><orcidid>https://orcid.org/0000-0003-3243-8018</orcidid><orcidid>https://orcid.org/0000-0001-7432-1657</orcidid><orcidid>https://orcid.org/0000-0003-3511-2005</orcidid><orcidid>https://orcid.org/0000-0002-6957-9482</orcidid><orcidid>https://orcid.org/0000-0001-9172-0510</orcidid><orcidid>https://orcid.org/0000-0002-9846-0210</orcidid><orcidid>https://orcid.org/0000-0002-2089-3825</orcidid><orcidid>https://orcid.org/0000-0001-7105-6202</orcidid><orcidid>https://orcid.org/0000-0002-6163-2947</orcidid><orcidid>https://orcid.org/0000-0001-6596-7384</orcidid><orcidid>https://orcid.org/0000-0001-7105-6202</orcidid><orcidid>https://orcid.org/0000-0001-6181-281X</orcidid><orcidid>https://orcid.org/0000-0002-6957-9482</orcidid><orcidid>https://orcid.org/0000-0002-4228-3868</orcidid><orcidid>https://orcid.org/0000-0002-9846-0210</orcidid><orcidid>https://orcid.org/0000-0003-3243-8018</orcidid><orcidid>https://orcid.org/0000-0003-3511-2005</orcidid><orcidid>https://orcid.org/0000-0002-2966-7947</orcidid><orcidid>https://orcid.org/0000-0001-7432-1657</orcidid><orcidid>https://orcid.org/0000-0002-7131-9882</orcidid><orcidid>https://orcid.org/0000-0002-4041-9696</orcidid><orcidid>https://orcid.org/0000-0001-9172-0510</orcidid></search><sort><creationdate>202010</creationdate><title>Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints</title><author>Farfour, E. ; Degand, N. ; Riverain, E. ; Fihman, V. ; Le Brun, C. ; Péan de Ponfilly, G. ; Muggeo, A. ; Jousset, A. ; Piau, C. ; Lesprit, P. ; Chatelain, N. ; Dortet, L. ; Poisson, A. ; Guillard, T. ; Limelette, A. ; Mizrahi, A. ; Le Monnier, A. ; Fournier, D. ; Potron, A. ; Morand, P. ; Janvier, F. ; Otto, M.-P. ; Woerther, P.-L. ; Decousser, J.-W. ; Corvec, S. ; Plouzeau-Jayle, C. ; Broutin, L. ; Yin, N. ; Héry-Arnaud, G. ; Beauruelle, C. ; Grillon, A. ; Lecuru, M. ; Bille, E. ; Godreuil, S. ; Jean Pierre, H. ; Amara, M. ; Henry, A. ; Zahar, J.-R. ; Carbonelle, E. ; Jaureguy, F. ; Lomont, A. ; Isnard, C. ; Cattoir, V. ; Canis, F. ; Diedrich, T. ; Flevin, E. ; Merens, A. ; Jacquier, H. ; Gyde, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hal_primary_oai_HAL_hal_04226097v13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anti-Bacterial Agents</topic><topic>Bacteria</topic><topic>Drug Resistance, Bacterial</topic><topic>Environmental Sciences</topic><topic>Fosfomycin</topic><topic>Microbial Sensitivity Tests</topic><topic>Practice Guidelines as Topic</topic><toplevel>online_resources</toplevel><creatorcontrib>Farfour, E.</creatorcontrib><creatorcontrib>Degand, N.</creatorcontrib><creatorcontrib>Riverain, E.</creatorcontrib><creatorcontrib>Fihman, V.</creatorcontrib><creatorcontrib>Le Brun, C.</creatorcontrib><creatorcontrib>Péan de Ponfilly, G.</creatorcontrib><creatorcontrib>Muggeo, A.</creatorcontrib><creatorcontrib>Jousset, A.</creatorcontrib><creatorcontrib>Piau, C.</creatorcontrib><creatorcontrib>Lesprit, P.</creatorcontrib><creatorcontrib>Chatelain, N.</creatorcontrib><creatorcontrib>Dortet, L.</creatorcontrib><creatorcontrib>Poisson, A.</creatorcontrib><creatorcontrib>Guillard, T.</creatorcontrib><creatorcontrib>Limelette, A.</creatorcontrib><creatorcontrib>Mizrahi, A.</creatorcontrib><creatorcontrib>Le Monnier, A.</creatorcontrib><creatorcontrib>Fournier, D.</creatorcontrib><creatorcontrib>Potron, A.</creatorcontrib><creatorcontrib>Morand, P.</creatorcontrib><creatorcontrib>Janvier, F.</creatorcontrib><creatorcontrib>Otto, M.-P.</creatorcontrib><creatorcontrib>Woerther, P.-L.</creatorcontrib><creatorcontrib>Decousser, J.-W.</creatorcontrib><creatorcontrib>Corvec, S.</creatorcontrib><creatorcontrib>Plouzeau-Jayle, C.</creatorcontrib><creatorcontrib>Broutin, L.</creatorcontrib><creatorcontrib>Yin, N.</creatorcontrib><creatorcontrib>Héry-Arnaud, G.</creatorcontrib><creatorcontrib>Beauruelle, C.</creatorcontrib><creatorcontrib>Grillon, A.</creatorcontrib><creatorcontrib>Lecuru, M.</creatorcontrib><creatorcontrib>Bille, E.</creatorcontrib><creatorcontrib>Godreuil, S.</creatorcontrib><creatorcontrib>Jean Pierre, H.</creatorcontrib><creatorcontrib>Amara, M.</creatorcontrib><creatorcontrib>Henry, A.</creatorcontrib><creatorcontrib>Zahar, J.-R.</creatorcontrib><creatorcontrib>Carbonelle, E.</creatorcontrib><creatorcontrib>Jaureguy, F.</creatorcontrib><creatorcontrib>Lomont, A.</creatorcontrib><creatorcontrib>Isnard, C.</creatorcontrib><creatorcontrib>Cattoir, V.</creatorcontrib><creatorcontrib>Canis, F.</creatorcontrib><creatorcontrib>Diedrich, T.</creatorcontrib><creatorcontrib>Flevin, E.</creatorcontrib><creatorcontrib>Merens, A.</creatorcontrib><creatorcontrib>Jacquier, H.</creatorcontrib><creatorcontrib>Gyde, E.</creatorcontrib><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Médecine et maladies infectieuses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farfour, E.</au><au>Degand, N.</au><au>Riverain, E.</au><au>Fihman, V.</au><au>Le Brun, C.</au><au>Péan de Ponfilly, G.</au><au>Muggeo, A.</au><au>Jousset, A.</au><au>Piau, C.</au><au>Lesprit, P.</au><au>Chatelain, N.</au><au>Dortet, L.</au><au>Poisson, A.</au><au>Guillard, T.</au><au>Limelette, A.</au><au>Mizrahi, A.</au><au>Le Monnier, A.</au><au>Fournier, D.</au><au>Potron, A.</au><au>Morand, P.</au><au>Janvier, F.</au><au>Otto, M.-P.</au><au>Woerther, P.-L.</au><au>Decousser, J.-W.</au><au>Corvec, S.</au><au>Plouzeau-Jayle, C.</au><au>Broutin, L.</au><au>Yin, N.</au><au>Héry-Arnaud, G.</au><au>Beauruelle, C.</au><au>Grillon, A.</au><au>Lecuru, M.</au><au>Bille, E.</au><au>Godreuil, S.</au><au>Jean Pierre, H.</au><au>Amara, M.</au><au>Henry, A.</au><au>Zahar, J.-R.</au><au>Carbonelle, E.</au><au>Jaureguy, F.</au><au>Lomont, A.</au><au>Isnard, C.</au><au>Cattoir, V.</au><au>Canis, F.</au><au>Diedrich, T.</au><au>Flevin, E.</au><au>Merens, A.</au><au>Jacquier, H.</au><au>Gyde, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints</atitle><jtitle>Médecine et maladies infectieuses</jtitle><date>2020-10</date><risdate>2020</risdate><volume>50</volume><issue>7</issue><spage>611</spage><epage>616</epage><pages>611-616</pages><issn>0399-077X</issn><abstract>The fosfomycin breakpoint using the disc diffusion method (DDM) changed in the 2019 CA-SFM/EUCAST guidelines v2 (24mm versus 19mm). We assessed its impact on categorization of Enterobacterales recovered from urine samples in emergency departments. A total of 7749 and 2348 strains were tested using the DDM and the broth microdilution method (BMD), respectively. The DDM with the 19-mm breakpoint was in accordance with the BMD. Using the 24-mm breakpoint, the overall rate of fosfomycin resistance in Enterobacterales increased by three-fold (5.6% vs 18.1%, P<0.01) and reached 2.8% and 86.5% in E. coli and K. pneumoniae, respectively. French guidelines for the management of community-acquired UTI remain appropriate. The accuracy of the methods for routine fosfomycin susceptibility testing should be assessed. The role of fosfomycin in the treatment of documented CA-UTI due to Enterobacterales other than E. coli should be evaluated considering its rate of resistance and recent data reporting low accuracy.</abstract><pub>Elsevier Masson</pub><pmid>32679342</pmid><doi>10.1016/j.medmal.2020.07.003</doi><orcidid>https://orcid.org/0000-0002-4041-9696</orcidid><orcidid>https://orcid.org/0000-0002-4228-3868</orcidid><orcidid>https://orcid.org/0000-0002-7131-9882</orcidid><orcidid>https://orcid.org/0000-0001-6596-7384</orcidid><orcidid>https://orcid.org/0000-0002-2966-7947</orcidid><orcidid>https://orcid.org/0000-0001-6181-281X</orcidid><orcidid>https://orcid.org/0000-0002-6163-2947</orcidid><orcidid>https://orcid.org/0000-0003-3243-8018</orcidid><orcidid>https://orcid.org/0000-0001-7432-1657</orcidid><orcidid>https://orcid.org/0000-0003-3511-2005</orcidid><orcidid>https://orcid.org/0000-0002-6957-9482</orcidid><orcidid>https://orcid.org/0000-0001-9172-0510</orcidid><orcidid>https://orcid.org/0000-0002-9846-0210</orcidid><orcidid>https://orcid.org/0000-0002-2089-3825</orcidid><orcidid>https://orcid.org/0000-0001-7105-6202</orcidid><orcidid>https://orcid.org/0000-0002-6163-2947</orcidid><orcidid>https://orcid.org/0000-0001-6596-7384</orcidid><orcidid>https://orcid.org/0000-0001-7105-6202</orcidid><orcidid>https://orcid.org/0000-0001-6181-281X</orcidid><orcidid>https://orcid.org/0000-0002-6957-9482</orcidid><orcidid>https://orcid.org/0000-0002-4228-3868</orcidid><orcidid>https://orcid.org/0000-0002-9846-0210</orcidid><orcidid>https://orcid.org/0000-0003-3243-8018</orcidid><orcidid>https://orcid.org/0000-0003-3511-2005</orcidid><orcidid>https://orcid.org/0000-0002-2966-7947</orcidid><orcidid>https://orcid.org/0000-0001-7432-1657</orcidid><orcidid>https://orcid.org/0000-0002-7131-9882</orcidid><orcidid>https://orcid.org/0000-0002-4041-9696</orcidid><orcidid>https://orcid.org/0000-0001-9172-0510</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0399-077X |
| ispartof | Médecine et maladies infectieuses, 2020-10, Vol.50 (7), p.611-616 |
| issn | 0399-077X |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04226097v1 |
| source | Elsevier ScienceDirect Journals |
| subjects | Anti-Bacterial Agents Bacteria Drug Resistance, Bacterial Environmental Sciences Fosfomycin Microbial Sensitivity Tests Practice Guidelines as Topic |
| title | Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A18%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fosfomycin,%20from%20susceptibility%20to%20resistance:%20Impact%20of%20the%20new%20guidelines%20on%20breakpoints&rft.jtitle=Me%CC%81decine%20et%20maladies%20infectieuses&rft.au=Farfour,%20E.&rft.date=2020-10&rft.volume=50&rft.issue=7&rft.spage=611&rft.epage=616&rft.pages=611-616&rft.issn=0399-077X&rft_id=info:doi/10.1016/j.medmal.2020.07.003&rft_dat=%3Chal%3Eoai_HAL_hal_04226097v1%3C/hal%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32679342&rfr_iscdi=true |